White PaperFebruary 2026ArthurAI™ University Learning Edition
The Case for AI Competency in PharmD Education.
Why tomorrow's pharmacists must learn to supervise, audit, and override the systems that will define their practice.
Chief Executive Officer, California Northstate University
ArthurAI™ University Learning Edition
Artificial intelligence is no longer a speculative technology in pharmacy practice. AI-powered clinical decision support systems are already deployed in hospital pharmacies across the United States — from automated medication verification to predictive models for adverse drug events. Yet the vast majority of Doctor of Pharmacy programs continue to graduate students without structured training in how these systems work, when they fail, and how to exercise clinical judgment in an AI-augmented environment.
The pharmacists graduating from CNU's accelerated three-year PharmD program in 2028 and 2029 will enter clinical environments where AI-driven dosing algorithms, predictive risk models, pharmacogenomic decision engines, and automated dispensing systems are standard infrastructure. Their ability to supervise, audit, and override these systems will directly determine patient safety outcomes, their professional value within interdisciplinary teams, and their long-term career resilience.
The most dangerous pharmacist in 2028 is not the one who refuses to use AI. It is the one who trusts it without understanding it.
Patient safety. Professional liability. Career resilience. Curricular leadership.
The profession is being redefined.
AI systems automate the cognitive tasks that historically justified the pharmacist's clinical role: drug interaction screening, dosage verification, therapy selection, formulary management. Robotic dispensing absorbs the operational workflow. The pharmacists who remain indispensable are those who can sit above the technology as clinical supervisors — the human-in-the-loop healthcare systems are legally, ethically, and practically required to maintain.
The patient safety imperative.
AI systems operate on data that may be incomplete, stale, or unrepresentative. When a hospital's AI flags a patient for VTE risk, when a smart infusion pump suggests a flow rate from a renal dosing algorithm, when a pharmacogenomic platform recommends an RAAS inhibitor based on genotype data — someone must understand the algorithm well enough to recognize when its confidence does not justify the clinical decision. A PharmD who cannot validate an AI-generated dose calculation is not equipped to provide meaningful oversight.
The evolving standard of care.
Courts evaluating AI-augmented care have begun examining whether clinicians exercised appropriate oversight of automated systems, not merely whether they followed the system’s recommendations. The Federation of State Medical Boards, the International Pharmaceutical Federation, and the American College of Clinical Pharmacy have all published guidance emphasizing AI oversight as an emerging professional competency. ACPE Standards 2025 explicitly encourage curricular innovation in this direction.
Career resilience and workforce value.
Health systems are creating roles at the intersection of clinical pharmacy and informatics. Residencies are incorporating technology competencies. The pharmacist who graduates with AI competency embedded in their education has a tangible advantage in residency matching, job placement, and career advancement — a foundation that compounds over a thirty-year career.
Strategic positioning for CNU.
CNU has already led with the nation’s first 3+4 PharmD-MD and PharmD-DMD pathways. Integrating AI competency training through ArthurAI ULE extends that leadership without disrupting current curriculum, faculty ownership, or assessment structures. Version 1 preserves the existing syllabus; Version 2 adds the AI competency layer on top.
- 01International Pharmaceutical Federation (FIP) — Statement of Policy: Artificial Intelligence in Pharmacy Practice. The Hague, 2025.
- 02American College of Clinical Pharmacy (ACCP) — Wong et al., "Forecasting the Impact of Artificial Intelligence on Clinical Pharmacy Practice." J Am Coll Clin Pharm. 2025.
- 03Accreditation Council for Pharmacy Education (ACPE) — Standards 2025. Effective July 1, 2025.
- 04Federation of State Medical Boards (FSMB) — Navigating the Responsible and Ethical Incorporation of AI into Practice. 2025.
- 05Milbank Quarterly — "Artificial Intelligence and Liability in Medicine: Balancing Safety and Innovation." 2024.
- 06ASHP — Proceedings of the ASHP Autoverification Work Group: Findings and Guidance. Am J Health-Syst Pharm. 2025.